Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...

Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo ...

Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.

The guidelines are part of a national trend by municipal governments and private firms struggling to manage ballooning costs ...

Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

A new study finds people who take weight-loss drugs also cut back on alcohol consumption. Researchers think the drugs could ...

Ozempic — or any of the GLP-1 class of diet drugs that includes Wegovy and Mounjaro — hasn’t just changed our nation’s ...

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...